Zimmer Biomet Net Worth

Zimmer Biomet Net Worth Breakdown

  ZBH
The net worth of Zimmer Biomet Holdings is the difference between its total assets and liabilities. Zimmer Biomet's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Zimmer Biomet's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Zimmer Biomet's net worth can be used as a measure of its financial health and stability which can help investors to decide if Zimmer Biomet is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Zimmer Biomet Holdings stock.

Zimmer Biomet Net Worth Analysis

Zimmer Biomet's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Zimmer Biomet's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Zimmer Biomet's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Zimmer Biomet's net worth analysis. One common approach is to calculate Zimmer Biomet's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Zimmer Biomet's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Zimmer Biomet's net worth. This approach calculates the present value of Zimmer Biomet's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Zimmer Biomet's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Zimmer Biomet's net worth. This involves comparing Zimmer Biomet's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Zimmer Biomet's net worth relative to its peers.
To determine if Zimmer Biomet is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Zimmer Biomet's net worth research are outlined below:
Over 94.0% of the company outstanding shares are owned by institutional investors
Zimmer Biomet uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Zimmer Biomet Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Zimmer Biomet's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
8th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Follow Zimmer Biomet's market capitalization trends

The company currently falls under 'Large-Cap' category with a total capitalization of 22.25 B.

Project Zimmer Biomet's profitablity

The company has Net Profit Margin of 0.12 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.23 %, which entails that for every 100 dollars of revenue, it generated $0.23 of operating income.
When accessing Zimmer Biomet's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Zimmer Biomet's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Zimmer Biomet's profitability and make more informed investment decisions.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zimmer Biomet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zimmer Biomet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zimmer Biomet insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Michael Farrell over two months ago
Acquisition by Michael Farrell of 301 shares of Zimmer Biomet at 107.76 subject to Rule 16b-3
 
Shapiro Louis over two months ago
Acquisition by Shapiro Louis of 130 shares of Zimmer Biomet at 105.73 subject to Rule 16b-3
 
Suketu Upadhyay over three months ago
Disposition of 15948 shares by Suketu Upadhyay of Zimmer Biomet subject to Rule 16b-3
 
Suketu Upadhyay over three months ago
Disposition of 15948 shares by Suketu Upadhyay of Zimmer Biomet subject to Rule 16b-3
 
Kurdikar Devdatt over three months ago
Acquisition by Kurdikar Devdatt of 127 shares of Zimmer Biomet at 107.76 subject to Rule 16b-3
 
Robert Hagemann over six months ago
Acquisition by Robert Hagemann of 616 shares of Zimmer Biomet at 121.61 subject to Rule 16b-3
 
Van Zuilen Wilfred over six months ago
Disposition of 2633 shares by Van Zuilen Wilfred of Zimmer Biomet subject to Rule 16b-3
 
Sreelakshmi Kolli over six months ago
Acquisition by Sreelakshmi Kolli of 144 shares of Zimmer Biomet at 108.48 subject to Rule 16b-3
 
Paul Stellato over six months ago
Disposition of 627 shares by Paul Stellato of Zimmer Biomet subject to Rule 16b-3
 
Arthur Higgins over six months ago
Acquisition by Arthur Higgins of 1068 shares of Zimmer Biomet subject to Rule 16b-3
 
Van Zuilen Wilfred over six months ago
Acquisition by Van Zuilen Wilfred of 2163 shares of Zimmer Biomet subject to Rule 16b-3
 
Lori Winkler over a year ago
Disposition of tradable shares by Lori Winkler of Zimmer Biomet at 124.28 subject to Rule 16b-3
Zimmer Biomet time-series forecasting models is one of many Zimmer Biomet's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Zimmer Biomet's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Zimmer Biomet Earnings per Share Projection vs Actual

Zimmer Biomet Corporate Directors

Arthur HigginsIndependent DirectorProfile
Michael MichelsonIndependent DirectorProfile
Christopher BegleyLead Independent DirectorProfile
Betsy BernardIndependent DirectorProfile

Already Invested in Zimmer Biomet Holdings?

The danger of trading Zimmer Biomet Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zimmer Biomet is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zimmer Biomet. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zimmer Biomet Holdings is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.